nephrology Archives -

Ten months after ChemoCentryx scored an unexpected FDA approval for autoimmune disease therapy Tavneos, Amgen has swooped in

Amgen splashes out on ChemoCentryx and its blockbuster hopeful

https://pharmaphorum.com/news/amgen-splashes-out-on-chemocentryx-and-its-blockbuster-hopeful/

News/ News/ R&D

MorphoSys slims down, narrowing its focus to cancer

Phil Taylor HIBio, Immunology and inflammation, licensing, MorphoSys, nephrology, Oncology, partnering 0 Comment

MorphoSys seemingly inexorable shift into an oncology pure-play has continued with an out-licensing deal for two programmes in

MorphoSys slims down, narrowing its focus to cancer

https://pharmaphorum.com/news/morphosys-slims-down-narrowing-its-focus-to-cancer/

Market Access/ News/ News

Hansa gets NICE okay for Idefirix in kidney transplant patients

Phil Taylor Hansa Biopharma, Idefirix, nephrology, NHS, NICE, transplant 0 Comment

Sweden’s Hansa Biopharma has claimed a positive opinion from NICE for Idefirix, which becomes the first drug cleared

Hansa gets NICE okay for Idefirix in kidney transplant patients

https://pharmaphorum.com/news/hansa-gets-nice-okay-for-idefirix-in-kidney-transplant-patients/

News/ News/ Sales and Marketing

Australia’s CSL makes $11.7bn bid for Swiss pharma Vifor

Phil Taylor CSL, CSL Behring, iron deficiency, M&A, nephrology, Seqirus, Vifor Pharma 0 Comment

Australian biotech group CSL has agreed a deal to acquire Swiss drugmaker Vifor Pharma in an all-cash deal

Australia’s CSL makes $11.7bn bid for Swiss pharma Vifor

https://pharmaphorum.com/news/australias-csl-makes-11-7bn-bid-for-swiss-pharma-vifor/

News

Vifor builds in kidney disease with Sanifit, Inositec buys

Phil Taylor chronic kidney disease, Inositec, M&A, nephrology, Sanifit, Vifor Pharma 0 Comment

On the heels of a late-stage clinical trial failure, Vifor Pharma has moved to bolster its pipeline by

Vifor builds in kidney disease with Sanifit, Inositec buys

https://pharmaphorum.com/news/vifor-builds-in-kidney-disease-with-sanifit-inositec-buys/

News/ News/ R&D

Novartis’ iptacopan hits the mark in rare kidney disease C3G

Phil Taylor C3 glomerulopathy, complement therapeutics, iptacopan, nephrology, Novartis, rare disease 0 Comment

Novartis has chalked up another successful trial for its targeted factor B inhibitor iptacopan, an orally-active drug trying

Novartis’ iptacopan hits the mark in rare kidney disease C3G

https://pharmaphorum.com/news/novartis-iptacopan-hits-the-mark-in-rare-kidney-disease-c3g/

Ardelyx’s-ambition-to-revolutionise-kidney-treatment

News/ News/ R&D

Vifor, Angion organ damage drug fails phase 3 kidney transplant study

Phil Taylor Angion Biomedica, nephrology, transplant, Vifor Pharma 0 Comment

Vifor Pharma and partner Angion Biomedica have suffered another setback with their drug to prevent organ damage, this

Vifor, Angion organ damage drug fails phase 3 kidney transplant study

https://pharmaphorum.com/news/vifor-angion-organ-damage-drug-fails-phase-3-kidney-transplant-study/

Market Access/ News/ News

FDA rejects FibroGen/AZ’s roxadustat, asking for new trial

Phil Taylor AstraZeneca, chronic kidney disease, daprodustat, fda, FibroGen, GlaxoSmithKline, nephrology, roxadustat 0 Comment

The FDA has demanded another clinical trial of FibroGen and AstraZeneca’s roxadustat for anaemia caused by chronic kidney

FDA rejects FibroGen/AZ’s roxadustat, asking for new trial

https://pharmaphorum.com/news/fda-rejects-fibrogen-azs-roxadustat-asking-for-new-trial/

Market Access/ News/ News

FDA adcomm turns down FibroGen, AZ’s roxadustat for CKD anaemia

Phil Taylor AstraZeneca, chronic kidney disease, daprodustat, fda, FibroGen, GlaxoSmithKline, nephrology, roxadustat 0 Comment

Safety concerns seem to have scuppered any hope of a near-term approval for FibroGen and AstraZeneca’s roxadustat for

FDA adcomm turns down FibroGen, AZ’s roxadustat for CKD anaemia

https://pharmaphorum.com/news/fda-adcomm-turns-down-fibrogen-azs-roxadustat-for-ckd-anaemia/

Trending

nephrology

Login